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Abstract
Objective: Did the publication of the Women Health Initiative (WHI) trial in 2002 and the Million Women Study (MWS) in
2003 lead to changes in prescription rates of hormone replacement therapy (HRT). Therefore, we compare the prescribing of
HRT in 2004 (after) with that of 2001 (before the publications) in The Netherlands.
Method: Community pharmacy dispensing data from a population of approximately 500,000 patients in The Netherlands. Women
aged 40–74 years to whom at least one HRT prescription was dispensed in 2001 or 2004 were included. Annual prevalences
of HRT in 2001 and 2004 and the percentage change (2004 versus 2001) were calculated for overall HRT (excluding vaginal
products) and per HRT category (combined estrogens and progestagens, estrogens only, tibolon and vaginal preparations) and
age category.
Results: In 2001, 5.64% of the women aged 40–74 used HRT and this percentage declined to 2.39 in 2004. The use of vaginal
products among these women did not change, 1.76% in 2001 and 1.65% in 2004. The percentage change was highest in the
opposed HRT group (66% decrease) and in women aged 50–54 (64.4% decrease). In 2004, compared with 2001, the proportion
of long-term users (>3 year) increased with 12.7%.
Conclusions: In The Netherlands, after publication of the WHI study and the MWS the prescribing of HRT fell dramatically
whereas the prescribing of vaginal products did not change. Future patterns of HRT use should be monitored to know whether
this decrease will be sustained.
© 2005 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
In The Netherlands, hormone replacement therapy
(HRT) is licensed for the alleviation of climacterial
symptoms and the prevention of osteoporosis, however
in daily practice, it was mainly prescribed for treatment0378-5122/$ – see front matter © 2005 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.maturitas.2005.10.010
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of vasomotor symptoms. HRT preparations used for
this purpose are either combined estrogens and pro-
gestagens (opposed) or estrogens alone (unopposed)
or tibolon. Vaginal applications, containing estriol or
dienestrel, are licensed for the relief of urogenital
symptoms.
Before 2002, HRT had been regarded as an inter-
vention with great potential benefits in terms of cardio-
vascular disease prevention and osteoporosis treatment
[1–3]. The publications of the Women Health Initiative
(WHI) trial results [4–6] and the results of the obser-
vational Million Women Study (MWS) [7] reported
increased rates of breast cancer, coronary heart dis-
eases, stroke, dementia and venous thromboembolism
and decreased rates of hip fractures and colorectal can-
cer in postmenopausal women using long-term HRT.
Both studies led to much attention and debate in the
medical and the lay press.
As a consequence, shortly after the publication of
the MWS the Dutch associations of gynaecologists and
general practitioners clearly stated that HRT should
be prescribed only in women with severe vasomo-
toric complaints in the lowest effective dose and for
a short period. According to the general practitioners
this period should not exceed 6 months and the recom-
mendations of the gyneacologists stated that the treat-
ment should be evaluated every 6–12 months [8,9]. The
European Medicines Agency for Drug Safety (EMEA)
stated in a position paper that for the initiation and con-














IADB covers all prescriptions from an estimated pop-
ulation of approximately 500,000 since 1999 [11,12].
Each prescription record contains among others name
of the drug, ATC-code, date of dispensing and amount
dispensed. Each patient has a unique, though anony-
mous identifier. Date of birth and gender of patients
are available. Due to a high patient–pharmacy commit-
ment in The Netherlands and sophisticated pharmacy
software, the medication records for each patient are
virtually complete [13]. This database comprises all
prescriptions, regardless of insurance or reimburse-
ment status, apart from drugs dispensed during hos-
pitalisations. Note that almost all HRT preparations
are fully reimbursed. Only for transdermal oestro-
gen/progestagen preparations a patient’s copayment is
required.
2.1. Study population and design
All women aged 40–74 years, to whom at least one
HRT prescription was dispensed in 2001 or in 2004
were selected from the IADB. Women who received
HRT prescription were classified into four categories:
(I) those who received conjugated estrogens or estra-
diol and progestagens either in a fixed combination
or separately (opposed), (II) those who only received
estrogens (conjugated estrogens or estradiol) (unop-
posed), (III) women who got tibolon and (IV) women
who received low potency estrogens (estriol or dien-

















phortest duration should be used. And in all cases, a
areful appraisal of the risks and benefits should be
ndertaken at least annually and HRT should only be
ontinued as long as benefits overweighs risks [10].
The aim of this report is to compare the use of HRT in
he Netherlands in 2004, after publication of the WHI
rial and the MWS results, with the use in 2001, the year
efore these publications. In addition, we compared
he duration of use among HRT-users before and after
ublication of both studies.
. Methods
This study was performed with the InterAction
atabase (IADB), which contains prescription drug
ispensing data from community pharmacies in the
orthern and eastern part of The Netherlands. Thetrophy. Tibolon is a synthetic steroid with weak estro-
enic, progestogenic and androgenic properties [14].
revalence of HRT prescribing was estimated per year
2001 and 2004) and was defined as the number of
omen (aged 40–74) to whom any HRT prescription
as dispensed per 100 women in the population cov-
red by the IADB. Annual prevalence was stratified
er HRT category and 5-years age categories. The per-
entage change, defined as: [(prevalence 2001 minus
revalence 2004) divided by prevalence 2001 multi-
lied by 100], was calculated and stratified per HRT
ategory.
For calculating the duration of use, we selected in
001 as well as in 2004 all HRT-users with at least
-year medication history in the database before the
rst prescription in 2001 or 2004. Of these HRT-users
e calculated the differences in proportion (2004 com-
ared to 2001) in relation to duration of use, being: less
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than 1 year, between 1 and 3 years, and more than 3-
year use.
For comparing prevalences of HRT use in 2004 with
2001 we used Pearson Chi-square.
3. Results
In 2001, of the 91,873 women aged 40–74, 5182
(5.64%) received at least a HRT preparation, licenced
for symptomatic treatment of vasomotor symptoms
or the prevention of osteoporosis and 1618 (1.67%)
received at least a vaginal low oestrogen product for
vaginal atrophy. In 2004, these prevalences were 2.39
and 1.65, respectively. The prevalence in the different
age categories of these two groups is shown in Fig. 1. A
dramatic decrease in the prescribing of HRT is seen in
all age categories, being the highest among the 50–54
(64.4% decrease) and the lowest among women aged
65–69 (40.3% decrease). For the low potency estrogens
the prevalence of use did not change between 2001 and
2004. These products, aimed for vaginal atrophy, are
prescribed to older women as can been seen in the fig-
ure.
Table 1 presents the percentage change in HRT
use for overall HRT (all categories, excluding vaginal
products), and per HRT category; combined estrogens
and progestagens, estrogens only, tibolon and vagi-
nal preparations. Between 2004 and 2001, the overall







HRT decreased most (66.0%), while the prevalence of
tibolon changed from 0.71 in 2001 to 0.45 in 2004
(36.6% decrease).
Table 2 shows the differences in proportion (2004
compared with 2001) among HRT-users in relation
to duration of use. Although the absolute numbers of
HRT-users dropped from 4194 in 2001 to 2130 in 2004,
the proportion of long-term users (>3 year) increased
with 12.7% in 2004 compared with 2001. The changes
in proportions of women who used HRT less than 1
year, and those who used it between 1 and 3 year were
lower, −8 and −4.7%, respectively.
4. Discussion
Between 2001 and 2004, the prevalence of HRT
use declined from 5.64 to 2.39% among women aged
40–74, whereas the use of vaginal products contain-
ing low potency estrogens did not change at all (1.76
and 1.65%, respectively). The decline in use was
most pronounced among women who were prescribed
combined estrogens and progestagens (65% decrease)
and estrogens only (54.2% decrease). The proportion
of long-term users among HRT-users increased with
12.7% in 2004 compared with 2001.
Before the release of the publications of WHI and
MWS the prescribing of HRT (including vaginal appli-
cations) in The Netherlands among women aged 45–69

















Zchange for the low-potency estrogens is much lower
−6.3%) and not significantly different (p = 0.055).
mong the HRT-users the prescribing of opposed
ig. 1. Prevalences of HRT prescribing per age category in 2001
nd 2004 for general HRT (combined, estrogen only and tibolon,
xcluding vaginal HRT) and for vaginal HRT prescribing.ences reported in the UK and USA. Data from the UK
how a prevalence of 27.7% in 1998 among women
ged 45–64 [16] and in the US these percentages vary
etween 38 and 50% [17,18]. In contrast with the US
nd the UK, HRT treatment for the prevention of car-
iovascular disease and osteoporosis with consequent
ong-term treatment duration was never prevalent in
he Netherlands. Dutch prescribers have always been
ery conservative in prescribing HRT, resulting in 2004
n a very low prevalence of use: 2.39 among 40–74 year
lds and 2.95 in women aged 45–69.
A decline in HRT use is also evaluated with prescrip-
ion claims data in the US [18,19]. Hersh et al. showed a
7% decrease of HRT prescriptions in 2003 compared
ith 1999 but in another study in a lower educated
opulation (Medicaid program) the decline was less
ronounced [19]. In a survey among HRT-users in New
ealand 40% stopped the use of HRT [20]. Our results
196 L.T.W. de Jong-van den Berg et al. / Maturitas 54 (2006) 193–197
Table 1
Prevalences of HRT in women aged 40–74 per HRT category and the % change in 2004 compared with 2001
Prevalence among women aged 40–74 years
2001 (n = 91873), N (prevalence) 2004 (n = 98401), N (prevalence) Change (%)b p-Valuea
All HRT (excluding vaginal) 5182 (5.64) 2351 (2.39) −57.62 <0.001
• Opposed HRT 2559 (2.79) 939 (0.95) −65.95 <0.001
• Oestrogens only 2069 (2.25) 1018 (1.03) −54.22 <0.001
• Tibolon 652 (0.71) 440 (0.45) −36.62 <0.001
Low-potency estrogens 1618 (1.76) 1621 (1.65) −6.25 0.055
a p-Value indicates whether prevalences differ between 2001 and 2004 using Pearson Chi-square.
b % Change: prevalence 2001–prevalence 2004prevalence 2004 .
Table 2
Number of HRT-users in women aged 40–74 according to the duration of use (<1, 1–3 and >3 year) in 2001 and 2004, and the difference in
proportion in 2004 compared with 2001
Duration of use Number of HRT (excluding vaginal HRT) users (40–74 year) (at least 3 years data available)
2001 N (%) 2004 N (%) Difference in proportion 2004 vs. 2001 (%)
<1 year 1179 (28.1) 429 (20.1) −8.0
Between 1 and 3 years 850 (20.3) 332 (15.6) −4.7
>3 years 2165 (51.6) 1369 (64.3) +12.7
Overall 4194 (100) 2130 (100)
show a decline of 57.6% among women aged 40–74
who received HRT (excluding vaginal preparations).
The different percentage decline seen in the studies
can be explained by the method used, the age groups
involved and the definition of the HRT. As is shown
in this study, the decline among the different age cate-
gories varied from 64% (50–54 years) to 40% (65–69
years). Studies among different age groups will reveil
different percentages change. We also illustrated that
the use of vaginal estrogen products, used for vaginal
atrophy, did change only marginally (−6%), whereas
the decline of opposed HRT in the same age category
(40–74 years) declined drastically (66%). Combining
both types of HRT will consequently result in lower
percentages change.
Although the Dutch recommendations stated that
HRT should be used only in women with severe com-
plaints and during of short time, we see in 2004 among
HRT-users a greater proportion of long-term users (>3
year) 64.3% compared with 51.6% in 2001, whereas
the proportion of short-term users (<1 year and between
1–3 years) declined. One explanation may relate to the
beneficial effects in women with severe menopausal
complaints. A recent Dutch survey showed that short-
term considerations prevail in deciding to continue or
stop the use of HRT for women who used the medica-
tion for a longer time [21].
In summary, we described a 57.6% decrease in the
prevalence of HRT-users in 2004 compared with 2001.
This 57.6% decrease in a population with an exist-
ing low prevalence of HRT use resulted in 2004 in an
overall prevalence of less than 3%. The prevalence of
vaginal low-potency estrogens did not change in the
same population. We will monitor future patterns of
HRT use to know whether this decrease will be sus-
tained.
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